Guidance Lists Suspect Product Scenarios Requiring FDA Notification

By January 17, 2017 Drug GMP Report No Comments

The FDA finalized guidance in December on suspect products and notification, describing when to file a report, and added example scenarios of fraudulent activity that would warrant alerting the agency, trading partners and wholesale distributors.
Source: Drug GMP Report